Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study

Bibliography

• Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21:959-69
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Dedoussis GV, Anagnostopoulou KK, et al. Management of a patient with a null low-density lipoprotein receptor mutation: a case report. Angiology 2006;57:729-32
   PubMedGoogle Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-76
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Saougos V, et al. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch Med Sci 2007;3:344-50
   Web of Science ®Google Scholar
• Luk T, Malam Z, Marshall JC: Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16
   PubMed Web of Science ®Google Scholar
• Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11:344-7
   PubMed Web of Science ®Google Scholar
• Pilz S, Mangge H, Obermayer-Pietsch B, Marz W. Visfatin/Pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 2007;30:138-44
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008;38:71-2
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323-6
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275-88
   PubMed Web of Science ®Google Scholar
• Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851-66
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37
   PubMed Web of Science ®Google Scholar
• Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27:2236-43
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008;578:249-52
   PubMed Web of Science ®Google Scholar
• Mauser W, Perwitz N, Meier B, et al. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007;564:37-46
   PubMed Web of Science ®Google Scholar
• Wang P, Van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007;454:971-6
   PubMed Web of Science ®Google Scholar
• Sun G, Bishop J, Khalili S, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007;85:399-404
   PubMedGoogle Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007;30:1278-80
   PubMedGoogle Scholar
• De Luis DA, Sagrado MG, Conde R, et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008;24:517-21
   PubMed Web of Science ®Google Scholar
• Smith J, Al-Amri M, Sniderman A, Cianflone K. Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1. Clin Endocrinol (Oxf) 2006;65:667-72
   PubMed Web of Science ®Google Scholar
• Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007;56:1216-20
   PubMed Web of Science ®Google Scholar
• Nakou E, Filippatos T, Liberopoulos E, et al. Effects of sibutramine plus verapamil SR/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharm 2008;9:1629-39
   PubMed Web of Science ®Google Scholar
• Oki K, Koide J, Nakanishi S, et al. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocrinol J 2007;54:431-5
   PubMedGoogle Scholar
• Filippatos TD, Derdemezis CS, Georgoula M, et al. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res 2007;2:9-10
   Google Scholar
• Pfutzner A, Hanefeld M, Lubben G, et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk – results from the PIOSTAT Study. Horm Metab Res 2007;39:764-8
   PubMedGoogle Scholar
• Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58
   PubMed Web of Science ®Google Scholar
• Takebayashi K, Suetsugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007;56:451-8
   PubMed Web of Science ®Google Scholar
• Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972-80
   PubMed Web of Science ®Google Scholar